Hologic Buys Interlace Medical, Acquires Missing Link In Gynecology Surgery
Executive Summary
Gynecologists generally have the opportunity to perform in-office procedures for three indications: abnormal uterine bleeding, permanent contraception and uterine fibroids. Hologic had supplied its 460 medical device reps in the US - the largest force in women's health - with the tools to perform two of these procedures, but couldn't offer the third piece of the puzzle, an in-office treatment for fibroids, a gap which, until now, hasn't been filled by any product on the market. Hologic is filling in the missing piece with the acquisition of privately held Interlace Medical, a start-up developing MyoSure, a minimally invasive resection device for submucosal fibroids.
You may also be interested in...
Building Interventional Gynecology
Once a sluggish category for clinical innovation, gynecology is drawing new venture-backed companies eager to build upon the lead created by first-generation companies operating in minimally-invasive endometrial ablation and female sterilization. First generation companies had the difficult task of creating paths to early adopters of minimally invasive procedures. These now exist, and the clinical specialty appears to be also evolving in ways that encourage the growth of in-office procedures.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.